Blair William & Co. IL Purchases 3,140 Shares of VanEck Pharmaceutical ETF $PPH

Blair William & Co. IL lifted its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 34.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,295 shares of the company’s stock after buying an additional 3,140 shares during the quarter. Blair William & Co. IL owned approximately 0.22% of VanEck Pharmaceutical ETF worth $1,081,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. U.S. Capital Wealth Advisors LLC grew its position in shares of VanEck Pharmaceutical ETF by 5.8% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 2,750 shares of the company’s stock worth $242,000 after buying an additional 150 shares in the last quarter. Adamsbrown Wealth Consultants LLC lifted its stake in shares of VanEck Pharmaceutical ETF by 12.0% during the 2nd quarter. Adamsbrown Wealth Consultants LLC now owns 195,976 shares of the company’s stock worth $17,238,000 after purchasing an additional 21,074 shares during the last quarter. Belpointe Asset Management LLC purchased a new stake in shares of VanEck Pharmaceutical ETF during the 1st quarter worth $528,000. NewEdge Advisors LLC lifted its stake in shares of VanEck Pharmaceutical ETF by 7.3% during the 1st quarter. NewEdge Advisors LLC now owns 8,873 shares of the company’s stock worth $809,000 after purchasing an additional 607 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of VanEck Pharmaceutical ETF by 53.3% during the 1st quarter. Royal Bank of Canada now owns 67,596 shares of the company’s stock worth $6,160,000 after purchasing an additional 23,491 shares during the last quarter.

VanEck Pharmaceutical ETF Price Performance

Shares of NASDAQ PPH opened at $92.13 on Thursday. The stock has a market capitalization of $1.24 billion, a P/E ratio of 20.21 and a beta of 0.72. VanEck Pharmaceutical ETF has a 1-year low of $77.67 and a 1-year high of $95.13. The business has a fifty day moving average price of $89.01 and a 200 day moving average price of $87.55.

VanEck Pharmaceutical ETF Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, October 6th. Investors of record on Wednesday, October 1st were paid a dividend of $0.3931 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date was Wednesday, October 1st.

About VanEck Pharmaceutical ETF

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.